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Abstract
Background: The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom
BCG (Bacillus Calmette-Guerin) has failed or is contraindicated are recently increasing due to the development of
new drugs. Although agents like mitomycin C and BCG are routinely used, there is a need for more potent and/or
less-toxic agents. In this scenario, a new perspective is represented by P-MAPA (Protein Aggregate
Magnesium-Ammonium Phospholinoleate-Palmitoleate Anhydride), developed by Farmabrasilis (non-profit research
network). This study detailed and characterized the mechanisms of action of P-MAPA based on activation of
mediators of Toll-like Receptors (TLRs) 2 and 4 signaling pathways and p53 in regulating angiogenesis and
apoptosis in an animal model of NMIBC, as well as, compared these mechanisms with BCG treatment.
Results: Our results demonstrated the activation of the immune system by BCG (MyD88-dependent pathway)
resulted in increased inflammatory cytokines. However, P-MAPA intravesical immunotherapy led to distinct
activation of TLRs 2 and 4-mediated innate immune system, resulting in increased interferons signaling pathway
(TRIF-dependent pathway), which was more effective in the NMIBC treatment. Interferon signaling pathway
activation induced by P-MAPA led to increase of iNOS protein levels, resulting in apoptosis and histopathological
recovery. Additionally, P-MAPA immunotherapy increased wild-type p53 protein levels. The increased wild-type p53
protein levels were fundamental to NO-induced apoptosis and the up-regulation of BAX. Furthermore, interferon
signaling pathway induction and increased p53 protein levels by P-MAPA led to important antitumor effects, not
only suppressing abnormal cell proliferation, but also by preventing continuous expansion of tumor mass through
suppression of angiogenesis, which was characterized by decreased VEGF and increased endostatin protein levels.
Conclusions: Thus, P-MAPA immunotherapy could be considered an important therapeutic strategy for NMIBC, as
well as, opens a new perspective for treatment of patients that are refractory or resistant to BCG intravesical
therapy.
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Background
Bladder cancer (BC) is the fourth most incidence tumor
in men and the ninth in women, showing high morbidity
and mortality rates [1, 2]. More than 70 % of BC is
superficial (non-muscle invasive bladder cancer) and
classified into 3 stages: pTis (flat carcinoma in situ), pTa
(papillary carcinoma non-invasive) and pT1 (tumor in-
vading mucosa or submucosa of the bladder wall) [3, 4].
Despite the prognosis associated with non-muscle inva-
sive bladder tumours, almost 50 % of patients will ex-
perience recurrence of their disease within 4 years of
their initial diagnosis, and 11 % will progress to muscle
invasive disease [3].
The primary treatment for high-grade NMIBC is based
on surgery by transurethral resection of bladder tumor
(TURBT), followed by intravesical immunotherapy with
Bacillus Calmette–Guerin (BCG) [5]. The response in-
duced by BCG reflects induction of a T-helper type-1
(Th1) response to prevent recurrence and to reduce
tumor progression [5–7]. However, BCG therapy shows
several undesirable effects that are observed up to 90 %
of patients, such as fever, chills, fatigue, irritative symp-
toms, haematuria and until major complications as
sepsis and death [8, 9].
Based on this background, compounds activating the
immune system, including vaccines, biological response
modifiers and tumor environment modulators are, con-
sidered potential candidates for the development of new
NMBIC treatments aiming to obtain greater therapeutic
effect combined with lower toxicity. Toll-like receptors
(TLRs) agonist compounds may represent a potential
antitumor therapeutic approach, as these receptors are
implicated in the pathogenesis of some tumors, includ-
ing NMIBC [10–12]. TLRs play key roles in innate im-
munity and their activation can trigger two different
responses in tumors: they stimulate immune system to
attack tumor cells and/or eliminate the inhibitory ma-
chinery to the immune system [13–15]. TLRs signaling
consist of two pathways: MyD88-dependent (canonical)
and TRIF-dependent (non-canonical) pathways [13–15].
Except for TLR3, the MyD88-dependent pathway acti-
vates NF-kB and MAPK, resulting in inflammatory cyto-
kines release, such as Tumor Necrosis Factor α (TNF-α)
and interleukin-6 (IL-6) [13, 14]. Conversely, the TRIF-
dependent pathway activates Interferon Regulatory Fac-
tor 3 (IRF-3) for the production of interferon [13–15].
TLR4 is the only receptor that uses the four adapter
molecules (MyD88, TRIF, TRAM and TIRAP) in a signal
cascade [13–15].
Most TLRs genes respond to p53 via canonical as well
as non-canonical promoter binding sites [16]. The p53
protein is responsible for cell cycle regulation, and it acts
as tumor suppressor [16, 17]. Studies of response el-
ement promoter sequences targeted by p53 suggest a
general role for p53 as a regulator of DNA damage and
as a control of TLRs gene expression [16]. Furthermore,
several studies suggested that antiangiogenic therapy is
sensitive to p53 status in tumors, indicating an import-
ant role of p53 in the regulation of angiogenesis [18, 19].
Angiogenesis plays a fundamental role in initiation and
progression in different tumors [20]. The vascular endo-
thelial growth factor (VEGF) stimulates all aspects of
endothelial function such as: proliferation, migration, pro-
duction of nitric oxide (NO) and endothelial cell layer
permeability [18, 20–22]. The angiogenesis inhibitors have
been developed to target endothelial cells and blocking
tumor blood supply [18, 23]. Endostatin is a potent en-
dogenous inhibitor of angiogenesis and induces apoptosis
in both endothelial cells and tumor cells [18, 19, 24].
Immunotherapy using compounds that act as TLR
agonists could be a valuable approach for cancer
treatment, whether used alone or in combination
with existing therapies. Protein aggregate magnesium-
ammonium phospholinoleate-palmitoleate anhydride
(P-MAPA) a biopolymer isolated in the 70′s [25] and
characterized in the years 90′s [26–28] currently
under development by Farmabrasilis (a nonprofit research
network) [29], has emerged as a potential candidate for
intravesical therapy for NMIBC. P-MAPA is a biological
response modifier obtained by fermentation from Asper-
gillus oryzae that demonstrates important antitumor effect
in several animal models of cancer, including NMIBC
[11, 12, 26–28]. Recent studies of our research group
demonstrated that P-MAPA modulates TLR 2 and 4
in both infectious diseases and cancer [11, 12, 30].
The strategy of research and development of the drug
P-MAPA is based in the concept of open source model,
with the researchers linked by a virtual research network
[29]. A complementary strategy adopted by Farmabrasilis
aims to booster the production of data to accelerate the
development of the compound as drug candidate for
cancer, including NMIBC, involves the selection of com-
pounds already in clinical use, and when available,
compounds equally able to act together with P-MAPA,
such as BCG, used in parallel or in conjunction with
experiments in vivo. The use of immunomodulatory com-
pounds already known against NMIBC with mechanisms
of action partially elucidated, such as BCG, in comparative
studies with P-MAPA using the same animal model, may
facilitate the visualization of commonalities, as well as the
differences in the mechanisms of action. Of note, these
data may also be relevant to understand the mode of ac-
tion of P-MAPA, aiming the elaboration of new strategies
focusing the future use of the compound for treatment of
some conditions that emerge in the treatment of NMIBC,
such as BCG refractory and BCG relapsing diseases.
Thus, this study presents the first comprehensive view
of the mechanisms of a potential therapeutic agent for
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NMIBC, P-MAPA biological response modifier, based
on activation of mediators of TLRs 2, 4 and p53 signal-
ing pathways in regulating the angiogenesis and apop-
tosis processes.
Methods
NMIBC induction and treatment
Forty female Fischer 344 rats, all 7 weeks old, were
obtained from the Multidisciplinary Center for Biological
Investigation (CEMIB) at University of Campinas (UNI-
CAMP). For the experiments the protocol followed
strictly the ethical principles in animal research (CEUA/
IB/UNICAMP–protocol number: 2684-1). Before each
intravesical catheterisation via a 22-gauge angiocatheter
treatments, animals were anesthetized with 10 % keta-
mine (60 mg/kg, i.m.; Ceva Animal Health Ltda, São
Paulo, Brazil) and 2 % xylazine (5 mg/kg, i.m.; Ceva
Animal Health Ltda, São Paulo, Brazil). The animals
remained anesthetized for approximately 45 min after
catheterization to prevent spontaneous micturition. Ten
control animals (CONTROL group) received 0.30 ml of
0.9 % physiological saline every other week for 14 weeks.
Thirty animals received 1.5 mg/Kg of n-methyl-n-nitro-
sourea (MNU) dissolved in 0.30 mL of sodium citrate
(1 M pH 6.0); each intravesically every other week for
8 weeks [11, 12]. Two weeks after the last dose of MNU,
all animals were submitted to retrograde cystography
and ultrasonography to evaluate the occurrence of
tumor. Both negative and positive contrast cystography
enabled the bladder wall, mucosal margin and lumen to
be visualised. For positive or negative contrast cystogra-
phies, animals were submitted to intravesical catheterisa-
tion via a 22-gauge angiocatheter to drain all the urine
from the bladder, instilled 0,3 mL of positive contrast
medium or 0,3 mL of air (negative contrast) into the
bladder until becomes slightly turgid (judged by palpa-
tion of the bladder through the abdominal wall) and
taken lateral and ventrodorsal radiographs.
The ultrasounds were evaluated using a portable,
software-controlled ultrasound system with a 10–5 MHz
38-mm linear array transducer.
The animals from CONTROL group showed no mass
infiltrating the bladder walls, as well as, there were no
vesicoureteral reflux and neither bladder filling defect
(Fig. 1a, b, c and d).
Negative contrast cystography and ultrasonography of
urinary bladder from MNU group showed a mass (average
tumor size 3,5 × 5,1 mm) infiltrating the ventral, dorsal
and cranial bladder walls (Fig. 1e, f and h). Positive
contrast cystography demonstrated several bladder filling
defects and vesicoureteral reflux unilateral (Fig. 1g) in
80 % of animals and bilateral in 10 % of animals.
MNU treated animals were further divided into three
groups (ten animals per group): the MNU group received
0.30 ml of 0.9 % physiological saline; the MNU-BCG
group received 106 CFU (40 mg) of BCG (Fundação
Ataulpho de Paiva, Rio de Janeiro, RJ, Brazil); the MNU-
P-MAPA group received 5 mg/kg dose of P-MAPA
(Farmabrasilis, Campinas, SP, Brazil). All animals were
treated every other week for 6 weeks. After the treatment,
the animals were euthanized and their urinary bladder
were collected and processed for histopathological, im-
munological and Western Blotting analysis.
Histopathological analysis
Samples of urinary bladders were used (n = 5) of each
group and fixed in Bouin solution for 12 h. Then, after the
fixation, the fragments were washed in 70 % ethanol, and
dehydrated in an ascending series of alcohols. Subse-
quently, the fragments were diaphanized in xylene for 2 h
and embedded in the plastic polymer (Paraplast Plus, ST.
Louis, MO, USA). Subsequently, the samples were cut on
a rotary microtome Slee CUT5062 RM 2165 (Slee
Mainz, Mainz, Germany), 5 μm thick, stained with
hematoxylin-eosin and photographed with a Leica
DM2500 photomicroscope (Leica, Munich, Germany).
A senior uropathologist analyzed the urinary bladder
lesions according to Health/World International Soci-
ety of Urological Pathology Organization [4].
Immunohistochemistry of toll-like receptor signaling
pathway: (TLR2, TLR4, MyD88, IRF-3, IKK-α, BAX, NF-kB,
iNOS, TNF-α, TRIF, IFN-γ, IL-6) and proliferation (Ki-67) in
NMIBC
The same samples as for histopathological analysis were
used for immunolabelings. They were cut into 6 μm
thick sections and antigen retrieval was performed either
by different protocols. Following that, the sections were
incubated in 0.3 % H2O2 to block endogenous peroxid-
ase, and nonspecific binding was blocked by incubating
the sections in blocking solution at room temperature.
The primary antibodies were: rabbit polyclonal anti-
TLR2 (251110, Abbiotec, San Diego, USA; 1:100), rabbit
polyclonal anti-TLR4 (251111, Abbiotec, San Diego,
USA; 1:100), rabbit polyclonal anti-MyD88 (ab2064;
1:75), rabbit polyclonal anti-IRF-3 (ab25950; 1:150),
rabbit polyclonal anti-IKK-α (ab38515; 1:100), rabbit
polyclonal anti-BAX (ab7977; 1:50), rabbit polyclonal
anti-NF-kB (ab7970; 1:200), rabbit polyclonal anti-iNOS
(ab15323; 1:75), rabbit polyclonal anti-TNF-α (ab6671;
1:150), rabbit polyclonal anti-TRIF (ab13810; 1:100),
rabbit polyclonal anti-IL-6 (ab6672; all the above from
Abcam, USA), mouse monoclonal anti-IFN-γ (507802,
Biolegend, USA;1:50) and mouse monoclonal anti- Ki-
67 (NCL-Ki67-MM1, Novocastra; Newcastle, United
Kingdom; 1:50). Antibodies were diluted in 1 % BSA
and applied to the sections overnight at 4 °C. Bound
antibodies were detected with an AdvanceTM HRP kit
Garcia et al. BMC Cancer  (2016) 16:422 Page 3 of 18
(Dako Cytomation Inc., USA). Sections were lightly
counterstained with Harris’ hematoxylin and pho-
tographed with a photomicroscope (DM2500 Leica,
Munich, Germany).
The immunohistochemistries were measured in five
animals in each experimental group, the same samples
as for histopathological analysis. Ten microscopic fields
per animal were measured with 40·objective lens and
corresponded to a total area of 92,500.8 μm2. TLR2,
TLR4, MyD88, IRF-3, IKK-α, BAX, NF-kB, iNOS, TNF-
α, TRIF, IFN-γ, IL-6 antibodies were scored semiquanti-
tatively by recording percentage of only urothelial cells.
At least 1,000 urothelial cells, for each group (200
urothelial cells per animal), were counted by the soft-
ware LAS V 3.7 (Leica, Munich, Germany) while the
examiner classified them as positive or negative cells.
Fig. 1 a–h Retrograde cystography and ultrasonography from CONTROL (a, b, c, d) and MNU (e, f, g, h) groups. Cystography without contrast
(a), negative (b) and positive (c) contrast cystographies, and ultrasounds (d) showed no mass infiltrating the bladder walls, as well as, there were
no vesicoureteral reflux and neither bladder filling defect. Cystography without contrast (e) and negative contrast cystography (f) showed a mass
infiltrating the ventral, dorsal and cranial bladder walls (asterisks). Positive contrast cystography (g) demonstrated several bladder filling defects
and vesicoureteral reflux unilateral (arrows). Ultrasound showed tumor (asterisk) infiltrating the bladder walls, tumor size: 1–3,9 mm, 2–5,5 mm
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Thus, the percentage of labeled cells (PLC) was de-
termined, according to the following equation:
PLC ¼ number of labelled cells=total counted cells
 100–expressed in : %
The PLC values were categorized into four scores as fol-
lows: 0, no immunoreactivity; 1, 1–35 % positive urothelial
cells; 2, 36–70 % positive urothelial cells; 3, > 70 % positive
urothelial cells. The software LAS V 3.7 (Leica, Munich,
Germany) was used to quantify the intensity of brownish-
color immunostaining. For each antibody, the same
photomicrographs used for determining the PLC were
considered. Ten randomized labeled nuclear and/or cyto-
plasmic regions from different urothelial cells were indi-
cated, with the same-sized square (software LAS V 3.7).
The average optical density (OD) of these areas was auto-
matically calculated and represents the average of red,
green, and blue color composition (RGB) per area of
nucleus and/or cytoplasm analyzed, expressed in optical
units per micrometer squared (ou/μm2). The same pro-
cedure was applied to obtain the background optical
density (BOD) from an area without tissue or vascular
space for each photomicrograph. A single area was
enough, since the background was constant in each
photomicrograph. The absolute white colour that corre-
sponds to the maximum optical density (MaxOD) was
composed by the totality of red, green, and blue; and black
was the absence of these colors. Therefore, the optical
density values calculated by the software make up a de-
creasing scale in which the high values correspond to the
colours that are visually clear.
The equation below was used to calculate the digital
immunostaining intensity (ITIdig) for each antibody,
whose values make up an increasing scale, equalized
by the BOD, proportionally to the optical density of
absolute white:
ITIdig ¼ MaxOD−MaxOD
X
OD=
X
BOD
–expressed in : ou=μm2
The intensity of reactivity was recorded as: weak (1+,
ITIdig average = 49.3 μm
2), moderate (2+, ITIdig aver-
age = 71.3 μm2) and intense (3+, ITIdig average = 95.1 μm
2).
Western blotting analysis of toll-like receptor signaling
pathway and angiogenesis: TLR2, MyD88, IKK-α, NF-kB,
TNF-α, IL-6, TLR4, TRIF, IRF-3, IFN-γ, iNOS, p53, vascular
endothelial growth factor (VEGF), endostatin BAX and
nod-like receptor 5 (NLRC5) in NMIBC
Samples of the urinary bladders were used (n = 5) of
each group, weighed (average 200 mg) and homoge-
nized in 50 μl/mg of RIPA lysis buffer (EMD Millipore
Corporation, Billerica, MA, USA). Aliquots containing
70 μg of protein were separated by SDS-PAGE on
10 % or 12 % polyacrylamide gels under reducing con-
ditions. After electrophoresis, the proteins were trans-
ferred to Hybond-ECL nitrocellulose membranes
(Amersham, Pharmacia Biotech, Arlington Heights,
IL., USA). The membranes were blocked with TBS-T
containing 1 % BSA (bovine serum albumin) and incu-
bated overnight at 4 °C with with primary rabbit poly-
clonal anti-TLR2 (ab13855; abcam, USA) polyclonal
rabbit anti-MyD88 (ab2064; abcam, USA), polyclonal
rabbit anti-IKK-α (ab38515; abcam, USA), polyclonal
rabbit anti-NF-kB (ab7970; abcam, USA), polyclonal
rabbit anti-TNF-α (ab6671; abcam, USA), polyclonal
rabbit anti-IL-6 (ab6672; abcam, USA), mouse mono-
clonal anti-TLR4 (ab30667; abcam, USA), polyclonal
rabbit anti-TRIF (ab13810; abcam, USA), polyclonal
rabbit anti-IRF-3 (ab25950; abcam, USA), mouse
monoclonal anti-IFN-γ (507802; Biolegend, USA),
polyclonal rabbit anti-iNOS (ab15323; abcam, USA),
mouse monoclonal anti-p53 (ab26; abcam, USA),
monoclonal mouse anti-VEGF (sc-53462; Santa Cruz
Biotechnology, USA), monoclonal mouse anti-Endostatin
(ab64569; abcam, USA), polyclonal rabbit anti-BAX
(ab7977; abcam, USA), polyclonal rabbit anti-NLRC5
(ab105411; abcam, USA) for diluted in 1 % BSA. The
membranes were then incubated for 2 h with rabbit or
mouse secondary HRP-conjugated antibodies (diluted
1:3,000 in 1 % BSA; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA). Peroxidase activity was detected by incu-
bation with a diaminobenzidine chromogen (Sigma Chem-
ical Co., St Louis, USA). Western blots were run in
duplicate, and urinary bladder samples were pooled from 5
animals per group for each repetition. The semi-
quantitative densitometry (IOD – Integrated Optical Dens-
ity) analysis of bands was conducted using NIH ImageJ
1.47v software (National Institute of Health, USA. Available
in: http://rsb.info.nih.gov/ij/), followed by statistical analysis.
β-actin was used as endogenous positive controls for
standardization of the readings of band staining intensity.
The results were expressed as the mean ± standard de-
viation of the ratio of each band’s intensity to β-actin
band intensity [12].
Determination of the proliferative index
Samples of the urinary bladders were randomly col-
lected from 5 animals in each group, the same used
for Ki-67 immunodetection and histopathology, and
used for determination of the proliferative index.
Ten fields were taken at random and measured per
animal, resulting in 50 fields per group with an × 40
objective lens and the total number of Ki-67 staining
positive cells was expressed as the percentage of
these total cells, including luminal and basal epit-
helial cells. Sections were lightly counterstained with
methyl green.
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Detection of apoptosis and determination of the
apoptotic index
Samples of the urinary bladders from five animals in each
group, the same used for immunodetection and histopath-
ology, were processed for DNA fragmentation (TUNEL) by
means of Terminal Deoxynucleotidyl Transferase (TdT),
using the Kit FragEL™ DNA (Calbiochem, La Jolla, CA,
USA). The apoptotic nuclei were identified using a diami-
nobenzidine chromogen mixture (Kit FragEL™ DNA). Ten
microscopic fields were randomly taken and analyzed per
sample, resulting in 50 fields per group, using a Leica
DM2500 (Leica, Munich, Germany) photomicroscope with
a × 40 objective. Sections were lightly counterstained with
methyl green. The apoptotic index was determined by
dividing the number of apoptotic nuclei by the total num-
ber of nuclei found in the microscope field.
Statistical analyses
Western Blotting, proliferative and apoptotic indexes
and proliferation/apoptotic ratio (P/A) were statisti-
cally compared among the groups by analysis of vari-
ance followed by the Turkey’s test with the level of
significance set at 1 %. Results were expressed as the
mean ± standard deviation. Histopathological analyses
were evaluated by proportion test. The difference be-
tween the two proportions was tested using test of
proportion. For all analyses, a type-I error of 5 % was
considered statistically significant.
Conclusion
Taking in account these present available data, the
mechanism of action of P-MAPA was clearly distinct in
relation to BCG. These important findings are relevant
concerning the treatment of patients with NMIBC
presenting high risk of progression that are refractory or
resistant to intravesical therapy with BCG.
Results
P-MAPA reverses the histopathological changes induced
by MNU
The urinary tract from the CONTROL group showed
no microscopic changes (Fig. 2a, b and c; Additional file
1: Table S1). The normal urothelium was composed of
three layers: a basal cell layer, an intermediate cell layer,
and a superficial layer composed of umbrella cells
(Fig. 2a, b, c).
In contrast, the urinary bladders from the MNU group
showed histopathological changes such as tumor invad-
ing mucosa or submucosa of the bladder wall (pT1)
(Fig. 2d, e and f), papillary carcinoma non-invasive (pTa)
and flat carcinoma in situ (pTis) in 40, 40 and 20 % of
the animals, respectively (Additional file 1: Table S1).
The keratinizing squamous metaplasia was found in
60 % of the animals (Fig. 2d and e).
The most frequent histopathological changes in the urin-
ary bladder from the MNU-BCG group were pTa (Fig. 2g,
h and i; Additional file 1: Table S1) low-grade intraurothe-
lial neoplasia and papillary hyperplasia in 40, 40 and 20 %
of the animals, respectively (Additional file 1: Table S1).
The microscopic features of the urinary bladders from
the MNU-P-MAPA group were similar to those found
in the CONTROL group (Fig. 2j, k and l). Normal
urothelium was found in 60 % of the animals (Fig. 2j
and k; Additional file 1: Table S1). The histopathological
changes in the MNU-P-MAPA group were flat hyper-
plasia (20 %) and papillary hyperplasia (20 %) (Fig. 2l;
Additional file 1: Table S1).
Urinary calculi and macroscopic haematuria were only
observed in the MNU and MNU-BCG groups; they were
absent in the MNU-P-MAPA group.
BCG activates MyD88-dependent pathway
The highest TLR2 protein levels were found in the
MNU-P-MAPA group as compared to the CONTROL,
MNU-BCG and MNU groups, showing intense immu-
noreactivities in the urothelium (Figs. 3a, g, m, s and 4;
Additional file 2: Table S2).
The highest MyD88 protein levels were found in the
MNU-BCG and MNU-P-MAPA groups as compared to
the other experimental groups. These groups showed in-
tense immunoreactivities in the urothelium (Figs. 3b, h,
n, t and 4; Additional file 2: Table S2). However, MyD88
levels were significantly higher in the CONTROL group
than in the MNU group; these groups exhibited moder-
ate and weak immunoreactivities, respectively (Figs. 3b,
h, n, t and 4; Additional file 2: Table S2).
IKK-α protein levels were significantly higher in the
MNU-BCG group in relation to the MNU, MNU-P-
MAPA and CONTROL groups, which showed intense,
moderate, weak and weak immunoreactivities in the
urothelium, respectively (Figs. 3c, i, o, u and 4; Additional
file 2: Table S2).
The highest NF-kB protein levels were found in the
MNU group as compared to the MNU-BCG, CON-
TROL and MNU-P-MAPA groups (Fig. 4). The NF-kB
immunoreactivities were weak in the cytoplasm of the
urothelial cells from the CONTROL group, intense in
both nucleus and cytoplasm of the urothelial cells from
the MNU group, moderate in both nucleus and cyto-
plasm of the urothelial cells from the MNU-BCG
group, and weak in the cytoplasm of the urothelial
cells from the MNU-P-MAPA group (Figs. 3d, j, p
and v; Additional file 2: Table S2).
TNF-α protein levels were significantly higher in the
MNU-BCG group than in all other experimental
groups, exhibiting intense immunoreactivities in the
urothelium (Figs. 3e, k, q, w and 4; Additional file 2:
Table S2). However, these levels were significantly
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higher in the MNU-P-MAPA and MNU groups in re-
lation to the CONTROL group, which showed weak,
intense and weak immunoreactivities, respectively
(Fig. 3e, k, q, w and 4; Additional file 2: Table S2).
IL-6 protein levels were significantly higher in the MNU-
BCG and MNU groups in relation to the MNU-P-MAPA
and CONTROL groups. These groups displayed intense,
intense, weak and weak immunoreactivities in the urothelium,
respectively (Figs. 3f, l, r, x and 4; Additional file 2: Table S2).
P-MAPA intravesical immunotherapy activates interferon
signaling pathway and increases iNOS levels
TLR4 protein levels were significantly higher in the MNU-
P-MAPA group in relation to the other experimental
Fig. 2 a–l Photomicrographs of the urinary bladder from CONTROL (a, b, c), MNU (d, e, f), MNU-BCG (g, h, i) and MNU-P-MAPA (j, k, l) groups.
a, b, c, j and k Normal urothelium composed of 2–3 layers: a basal cell layer (arrowhead), an intermediate cell layer (arrow), and a superficial or
apical layer composed of umbrella cells (open arrowhead). d, e and f pT1: neoplastic cells arranged in small groups (arrows) invading the lamina
propria; keratinizing squamous metaplasia (Sm). g, h and i pTa characterized by fibrovascular stalk and frequent papillary branching with increased
cellular size. l Papillary hyperplasia. a–l Lp lamina propria, M muscular layer, Ur urothelium
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groups. This group exhibited intense immunoreactivities in
the urothelium (Figs. 5a, g, m, s and 6; Additional file 2:
Table S2). However, these levels were significantly higher in
the CONTROL and MNU-BCG groups than in the MNU
group. The three latter groups showed moderate, intense
and weak immunoreactivities, respectively (Figs. 5a, g, m, s
and 6; Additional file 2: Table S2).
TRIF protein levels were significantly higher in the
MNU-P-MAPA group in relation to the other experimen-
tal groups, which showed intense immunoreactivities in
Fig. 3 Immunolabelled antigen intensities of the urinary bladder from the CONTROL (a, b, c, d, e, f), MNU (g, h, i, j, k, l), MNU-BCG (m, n, o, p,
q, r), and MNU-P-MAPA (s, t, u, v, w, x) groups. TLR2 immunoreactivities (asterisks) were moderate in the urothelium from the CONTROL (a)
group, weak in the MNU (g) group and intense in the MNU-BCG (m) and MNU-P-MAPA (s) groups. MyD88 immunoreactivities (asterisks) were
moderate in the urothelium from the CONTROL (b) group, weak in the MNU (h) group and intense in the MNU-BCG (n) and MNU-P-MAPA (t)
groups. IKK-α immunoreactivities (arrows) were weak in the urothelium from the CONTROL (c) group, moderate in the MNU (i) group, intense in
the MNU-BCG group (o) and weak in the MNU-P-MAPA (u) group. NF-kB immunoreactivities (arrows) were weak in the cytoplasm of the urothelial
cells from the CONTROL (d) group, intense in the nucleus and cytoplasm of the urothelial cells from the MNU (j) group, moderate in the nucleus and
cytoplasm of the urothelial cells from the MNU-BCG (p) group and weak in the cytoplasm of the urothelial cells from the MNU-P-MAPA (v) group.
TNF-α immunoreactivities (asterisks) were weak in the urothelium from the CONTROL (e) group, intense in the MNU (k) and MNU-BCG (q) groups
and weak in the MNU-P-MAPA (w) group. IL-6 immunoreactivities (asterisks) were weak in the urothelium from the CONTROL (f) group, intense in the
MNU (l) and MNU-BCG (r) groups and weak in the MNU-P-MAPA (x) group. a–x Ur urothelium
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Fig. 4 Representative Western Blotting and semiquantitative determination for TLR2, MyD88, IKK-α, NF-kB, TNF-α and IL-6 protein levels. Samples
of urinary bladder were pooled from five animals per group for each repetition (duplicate) and used for semi-quantitative densitometry
(IOD – Integrated Optical Density) analysis of the TLR2, MyD88, IKK-α, NF-kB, TNF-α and IL-6 levels following normalization to the β-actin.
All data were expressed as the mean ± standard deviation. Different lowercase letters (a, b, c, d) indicate significant differences (p <0.01)
between the groups after Tukey’s test
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the urothelium (Figs. 4b, h, n, t and 6; Additional file 2:
Table S2). However, TRIF levels were higher in the MNU-
BCG and MNU groups than in the CONTROL group.
The three latter groups exhibited moderate, weak and
weak immunoreactivities respectively (Figs. 5b, h, n, t and
6; Additional file 2: Table S2).
Protein levels for IRF-3 were significantly higher in the
MNU-BCG and MNU-P-MAPA groups in relation to
Fig. 5 Immunolabelled antigen intensities of the urinary bladder from the CONTROL (a, b, c, d, e, f), MNU (g, h, i, j, k, l), MNU-BCG (m, n, o, p,
q, r), and MNU-P-MAPA (s, t, u, v, w, x) groups. TLR4 immunoreactivities (asterisks) were moderate in the urothelium from the CONTROL group
(a), weak in the MNU group (g) and intense in the MNU-BCG (m) and MNU-P-MAPA (s) groups. TRIF immunoreactivities (asterisks) were weak in
the urothelium from the CONTROL (b) and MNU (h) groups, moderate in the MNU-BCG (n) group and intense in the MNU-P-MAPA (t) group.
IRF-3 immunoreactivities (arrows) were weak in the urothelium from the CONTROL (c) and MNU (i) groups, moderate in the MNU-BCG (o) group
and intense in the MNU-P-MAPA (u) group. IFN-γ immunoreactivities (arrows) were weak in the urothelium from the CONTROL (d) and MNU (j)
groups, moderate in the MNU-BCG (p) group and intense in the MNU-P-MAPA (v) group. iNOS immunoreactivities (asterisks) were weak in the
urothelium from the CONTROL (e) and MNU (k) groups, moderate in the MNU-BCG (q) group and intense in the MNU-P-MAPA (w) group. BAX
immunoreactivities (asterisks) were weak in the urothelium from the CONTROL (f) group, moderate in the MNU (l) and MNU-BCG (r) groups and
intense in the MNU-P-MAPA (x) group. a–x Ur urothelium
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Fig. 6 Representative Western Blotting and semiquantitative determination for TLR4, TRIF, IRF-3, IFN-γ, iNOS, and p53 protein levels.
Samples of urinary bladder were pooled from five animals per group for each repetition (duplicate) and used for semi-quantitative
densitometry (IOD – Integrated Optical Density) analysis of the TLR4, TRIF, IRF-3, IFN-γ, iNOS, and p53 levels following normalization to
the β-actin. All data were expressed as the mean ± standard deviation. Different lowercase letters (a, b, c, d) indicate significant
differences (p <0.01) between the groups after Tukey’s test
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the CONTROL and MNU groups. These groups showed
moderate, intense, weak and weak immunoreactivities
in the urothelium, respectively (Figs. 5c, i, o, u and 6;
Additional file 2: Table S2).
The highest IFN-γ protein levels were found in the
MNU-P-MAPA group compared to the MNU-BCG,
MNU and CONTROL groups. These groups exhibited
intense, moderate, weak and weak immunoreactivities
in the urothelium, respectively (Figs. 5d, j, p, v and 6;
Additional file 2: Table S2).
iNOS protein levels were significantly higher in the
MNU-P-MAPA and MNU-BCG groups than in the
MNU and CONTROL groups. These groups showed
intense, moderate, weak and weak immunoreactivities in
the urothelium, respectively (Figs. 5e, k, q, w and 6;
Additional file 2: Table S2).
NLRC5 protein levels were significantly higher in the
MNU-P-MAPA group in relation to the other experi-
mental groups (Fig. 7). Furthermore, these levels were
significantly higher in the CONTROL and MNU-BCG
groups than in the MNU group (Fig. 7).
P-MAPA immunotherapy increases wild-type p53 protein
levels, decreases proliferation and increases apoptosis
p53 protein levels were significantly higher in the MNU-
P-MAPA and CONTROL groups in relation to the other
experimental groups (Fig. 6). Furthermore, these levels
were significantly higher in the MNU-BCG group in
comparison to the MNU group (Fig. 6).
The apoptotic index revealed different kinetics for cell
death for each treatment (Additional file 3: Figures S1a,
S1c, S1e, S1g; Fig. 8). This index was significantly higher
in the animals from the MNU-P-MAPA group in rela-
tion to the other experimental groups. The MNU and
MNU-BCG groups, in turn, showed significantly higher
average values of the apoptotic index than the CON-
TROL group (Additional file 3: Figures S1a, S1c, S1e,
S1g; Fig. 8). BAX protein levels were significantly higher
in the MNU-P-MAPA group compared to the MNU,
MNU-BCG and CONTROL groups. The groups exhib-
ited intense, moderate, moderate and weak immunoreac-
tivities in the urothelium, respectively (Figs. 3f, l, r, x and
6; Additional file 2: Table S2).
Proliferative activity was significantly increased in ani-
mals from the MNU group in relation to the other experi-
mental groups (Additional file 3: Figures S1b, S1d, S1f,
S1h; Fig. 8). The MNU-P-MAPA group displayed signifi-
cantly lower average values of proliferative index than the
MNU-BCG group, although these values were signifi-
cantly higher than those found in the CONTROL group
(Additional file 3: Figures S1b, S1d, S1f, S1h; Fig. 8).
Furthermore, the proliferation/apoptotic ratio (P/A) was
significantly higher in the MNU and MNU-BCG groups
when compared to CONTROL group (Fig. 9). However,
the P/A ratio in the MNU-P-MAPA was significantly
lower in relation to the other experimental groups, indi-
cating predominance of the apoptotic process (Fig. 9).
P-MAPA intravesical immunotherapy suppresses
angiogenesis
VEGF protein levels were significantly higher in the
MNU group in relation to the other experimental groups
(Fig. 7). Furthermore, these levels were significantly
higher in the MNU-BCG group compared to the MNU-
P-MAPA and CONTROL groups (Fig. 7).
Endostatin protein levels were significantly higher in
the MNU-P-MAPA and CONTROL groups when com-
pared to the MNU-BCG and MNU groups (Fig. 7).
Discussion
Although the use of TURBT with adjuvant chemo and im-
munotherapy represents a clear advance in the treatment
of NMIBC, the management of this disease, mainly for
high grade tumors remains a challenge, because the high
rates of recurrence and progression to muscle invasive
and/or metastatic stages. Following episodes of high grade
NMIBC recurrence after BCG therapy, several conven-
tional chemotherapy agents have been used including
gemcitabine, mitomycin, gemcitabine plus mitomycin, do-
cetaxel and valrubicin. In addition, immunotherapy (Inter-
feron-alpha or Interferon alpha-plus BCG) has also been
used [31].Mycobacterium phlei cell wall-nucleic acid com-
plex (MCNA) has been proposed for intravesical treat-
ment of NMIBC at high risk of recurrence or progression
in patients who failed prior BCG immunotherapy (e.g., in
patients who are BCG-refractory or BCG relapsing) and
are not candidates for or refuse cystectomy [32]. However,
none of these drugs had been shown superiority over
BCG and remains considered investigational [14]. In the
specific case of BCG-refractory CIS, Valrubicin, a semi-
syntetic analog of doxorubicin, the only FDA-approved
drug for treatment of such condition, shows effectivity in
less of 10 % of treated patients at 2 years and none with
coincident stage T1 disease [33].
The surgical option for such cases, partial or total cyst-
ectomy, is often associated with significant morbidity and
mortality. Furthermore, for some patients, cystectomy is
not an available option due to the presence of concomi-
tant comorbidities. Consequently novel therapies are
highly needed for treatment of high grade NMIBC, to pre-
vent disease progression and to allow bladder preservation
and ensure life quality for patients and finally, to provide
an option for those that are ineligible for cystectomy.
The P-MAPA Biological Response Modifier, which
shows novel therapeutic properties compared to stand-
ard treatments, appears a valuable candidate drug in the
treatment of NMIBC. In our previous studies we have
shown several beneficial properties of P-MAPA [11, 12].
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Here, using the NMU animal models for the study of
NMIBC, we clearly show that P-MAPA treatment en-
ables better histopathological recovery from the cancer
state than no treatment (MNU group) or BCG treatment
(MNU-BCG group).
Agonists of TLRs are the subject of intensive research
and development for the treatment of cancer, including
bladder cancer [11, 12, 33]. TLRs, which are expressed in
immune as well as in some epithelial cells, play an
important role in activating both innate and adaptive im-
mune responses [33] and [33, 34]. Bladder tumors,
especially non-muscle-invasive, show decreased TLRs ex-
pression [35, 36]. TLR-mediated BCG immunotherapy for
NMIBCs suggests alternative TLR-based immunotherapies
Fig. 7 Representative Western Blotting and semiquantitative determination for VEGF, Endostatin, BAX and NLRC5 protein levels. Samples
of urinary bladder were pooled from five animals per group for each repetition (duplicate) and used for semi-quantitative densitometry
(IOD – Integrated Optical Density) analysis of the VEGF, Endostatin, BAX and NLRC5 levels following normalization to the β-actin. All data
were expressed as the mean ± standard deviation. Different lowercase letters (a, b, c, d) indicate significant differences (p <0.01) between
the groups after Tukey’s test
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might also be successful strategies for this type of cancer.
The BCG antitumor effects seem to be related to local im-
munological mechanisms since after BCG instillation, a
transient increase in several cytokines and the presence of
activated immunocompetent leukocytes were found in the
urine within 24 h [37]. Local lymphocytic infiltration and
cytokine production were found in the bladder wall of most
patients receiving intravesical BCG and was demonstrated
that this local response was highly complex [37–39]. TNF-
related-apoptosis-inducing ligand (TRAIL) is released from
polymorph nuclear neutrophils (PMNs) via stimulation of
TLR2 by BCG [33]. Secretion of interleukin-8, a strong
chemoattractant for monocytes and T-cells, is also induced
from PMNs by BCG infection via MyD88-dependent TLR2
and TLR4 activation [33, 40] whereas BCG activation of
TLR2 and TLR4 induces TNF-α secretion from dendritic
cells (DCs) [33, 41, 42].
TNF signaling pathway may induce carcinogenesis by
up-regulating NF-kB leading to the up-regulation of
other proteins that cause cell proliferation and morpho-
genesis [40]. Using TNF knockout mice the development
of skin carcinomas by chemical carcinogen DMBA
(7.12-dimethylbanz[a]-antracene) and tumor promoter
TPA (12-0-tetradecanoyl-phorbol-13-acetate) decreased
compared to wild type mice [43, 44]. Using pentoxifyl-
line, which was shown to inhibit TNF and IL-1a gene ex-
pression, the growth of DMBA/TPA induced papillomas
were inhibited [45]. These results suggest a chemical
tumor promoter can induce the secretion of TNF-α from
different cells types and TNF can act as an endogenous
tumor promoter in vivo [46]. TNF-α was identified as the
major host-produced factor that enhances the growth of
metastases in the lung cancer animal model, in part
through activation of NF-kB in the tumor cells [47].
Fig. 8 Percentage of Proliferative (Ki-67) and Apoptotic Indexes
Fig. 9 Proliferation/Apoptotic Ratio (P/A)
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We have demonstrated here that BCG increased TLR2
and TLR4 protein levels in NMIBC model, which corrobo-
rated with our previous study [11, 12]. These induces
MyD88-dependent pathway as shown by increased MyD88,
IKKα and NF-kB protein levels. The induction of
MyD88-dependent pathway or canonical pathway in-
creases inflammatory cytokines (IL-6 and TNF-α) pro-
tein levels. Accordingly, activation of immune system
by BCG treatment, via MyD88-dependent pathway,
(Additional file 4: Figure S2a), was essential for histo-
pathological recovery from the cancer state.
TLR4 activation of host macrophages resulted in the
production of several different inflammatory cytokines
that influenced tumor growth. However, TLR4 signaling
also induces cytokines (IFN) that have antitumor effects
by induction of TRAIL, a potent inducer of tumor cell
death [47]. Shankaran et al. [48] showed the tumorsup-
pressor function of the immune system to be critically
depend on the actions of IFN-γ, which, at least in part,
are driven to regule tumor-cell immunogenicity. IFN-γ
stimulates several antiproliferative and tumoricidal bio-
chemical pathways in macrophages and in tumor cell
lines, as well as has a profound impact on solid tumors
growth and metastasis and seemingly plays an early role
in protection from metastasis [49–55]. IFN-γ produced
by IL-12-activated tumor-infiltrating CD8+T cells dir-
ectly induced apoptosis of mouse hepatocellular carcin-
oma cells [52, 53]. The NLRCs, a class of intracellular
receptors that respond to pathogen or cellular stress, has
recently been identified as a critical regulator of immune
responses [56, 57]. While NLRC5 is constitutively and
widely expressed, its levels can be dramatically induced
by interferons during pathogen infections. Both in vitro
and in vivo studies have demonstrated NLRC5 is a
specific and master regulator of major histocompatibility
complex (MHC) class I genes as well as related genes
involved in MHC class I antigen presentation [56, 57].
In this study, we demonstrated TLR2 and TLR4 protein
levels were significantly higher in the P-MAPA group in
relation to the BCG group in the NMIBC animal model.
Also, P-MAPA treatment led to increased TRIF and IRF-3
protein levels, indicating an activation of MyD88-
independent pathway (Additional file 4: Figure S2b). The
induction of MyD88-independent pathway (non-canonical
pathway or TRIF-dependent pathway) by P-MAPA led to
increased IFN-γ and iNOS (macrophages type 1 – M1)
protein levels. In contrast to BCG treatment, P-MAPA
immunotherapy led to distinct activation of innate im-
mune system TLRs 2 and 4-mediated, resulting in in-
creased interferons signaling pathway (Additional file 4:
Figure S2b), which was more effective in the NMIBC
treatment. Also as result of interferon signaling pathway
(IFN-γ and IRF-3) induction by P-MAPA, the prolifera-
tion/apoptotic ratio was significantly lower in animals
treated with P-MAPA, indicating predominance of the
apoptotic process. Accordingly, P-MAPA immunotherapy
increased NOD like receptor 5 (NLRC5) protein levels,
which were fundamental to induction of interferon signal-
ing pathway (Additional file 4: Figure S2b). Thus, the acti-
vation of interferon signaling pathway was more effective
in the induction of immunogenic cell death in relation to
inflammatory cytokines signaling pathway.
The IFN-γ produced by tumor-infiltrating T cells might
play two distinct roles in antitumor activity: activation of
antitumor T cells and direct tumoricidal activity by gener-
ating inducible nitric oxide synthetase (iNOS) [48, 58].
NO is considered one of the main factors responsible for
the macrophage cytotoxic activity against tumor cells
[50, 59]. Previous data showing increased NO concen-
trations in the urinary bladder from patients treated
with BCG [59–61], suggests NO as a critical factor in
the BCG mediated antitumor effect [56]. NO can stimu-
late cell growth and cell differentiation when present at
low concentrations, whereas high concentrations often
result in cytotoxic effects [59]. Tate et al. [50] demon-
strated iNOS induction within the renal carcinoma cells
(CL-2 and CL-19) in response to IFN-γ caused a robust
and sustained accumulation of endogenous NO that
resulted in an 80–85 % growth inhibition of CL-2 and CL-
19 cell lines. Patients with bladder cancer who had
received BCG treatment, iNOS-like immunoreactivity was
found in the urothelial cells but also in macrophages in
the submucosa [56]. Koskela et al. [59] verified that
endogenously formed NO was significantly increased in
the BCG treated patients and they had a ten-fold increase
in mRNA expression for iNOS compared to healthy con-
trols. In culture supernatant from macrophages stimulated
by P-MAPA in both healthy and visceral leishmaniasis,
infected dogs NO production was increased [62]. Thus, it
can be concluded interferon signaling pathway activation
induced by P-MAPA led to increase of iNOS protein
levels in the NMIBC animal model, resulting in in-
creased apoptosis process and histopathological recov-
ery (Additional file 4: Figure S2b).
Furthermore, cell death may depend on NO-stimulated
signaling pathways leading to gene expression, involving
the tumor suppressor p53 [63–65]. Activation of p53 by
NO has been observed in many cell types [66, 67]. NO-
induced p53 contributes to various cell type-specific bio-
logical effects of NO, such as induction of apoptosis, in-
hibition of proliferation and tumor suppression [66–68].
Besides that, p53 controls a remarkable number of physio-
logic functions, including energy metabolism, differen-
tiation, and reactive oxygen species production and is
stabilized and activated in response to diverse stresses sig-
nals, such as DNA damage, hypoxia, oncogene activation,
drugs, nucleotide depletion [64]. Cells possessing a fully
functional p53 pathway can either arrest and repair
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damages caused by these untimely stresses or undergo p53-
dependent apoptosis. BAX is considered an important
target gene required for p53-dependent apoptosis [64].
Induction of p53 by NO is preceded by a rapid decrease in
Mdm2 protein, which may enable to elevate p53 levels early
after exposure to NO [67]. Wang et al. [67] showed NO
promoted p53 nuclear retention and inhibited Mdm2-
mediated p53 nuclear export, indicating this effect to be
mediated by ATM-dependent phosphorylation of p53 on
Serine 15. Also, In conclusion, these findings imply that,
through augmenting p53 nuclear retention NO can
sensitize tumor cells to p53-dependent apoptosis.
Several studies suggest antiangiogenic therapy is sensitive
to p53 status in tumors, implicating a role for p53 in the
regulation of angiogenesis [18, 19, 69]. A connection be-
tween p53 and tumor angiogenesis was revealed in 1994
when Dameron et al. [69] proposed suppression of angio-
genesis by thrombospondin-1 could represent a new mech-
anism for tumor suppression by p53. Other evidence
emerged that wild-type p53 could prevent incipient tumors
from becoming angiogenic [70]. Teodoro et al. [19] demon-
strated p53-tumor suppression was mediated in part by at
least two potent angiogenesis inhibitors, endostatin and
tumstatin. In addition, these authors showed ectopic ex-
pression of α (II) collagen prolyl-4-hydroxylase in human
tumor cells implanted into immunodeficient mice resulted
in “near-complete” tumor suppression compared with mice
implanted with tumor cells that did not express α (II) colla-
gen prolyl-4-hydroxylase, and associated this results with
suppression of tumor angiogenesis by endostatin or tumsta-
tin. Thus, this study demonstrated an important antitumor
effect of P-MAPA immunotherapy, based on increase of
endostatin protein levels and decrease of VEGF protein
levels in the NMIBC animal model. Therefore, interferon
signaling pathway induction and increased wild-type p53
protein levels by P-MAPA led to important antitumor
effects, not only suppressing abnormal cell proliferation,
but also by preventing continuous expansion of tumor
mass through suppression of angiogenesis.
Conclusions
Taking in account these present available data, the
mechanism of action of P-MAPA was clearly distinct in
relation to BCG. These important findings are relevant
concerning the treatment of patients with NMIBC pre-
senting high risk of progression that are refractory or re-
sistant to intravesical therapy with BCG.
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